Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Oral chronic graft versus host disease (cGVHD) is often refractory to systemic therapies. Additional topical treatment is commonly required. The potency of the agent, the vehicle and formulation in which it is delivered are all critical factors in determining the effectiveness of topical therapies. High potency of budesonide, combined with its very low bioavailability when absorbed through mucosal surfaces, increased the potential role in topical application for oral cGVHD. Viscous formulation increases mucosal contact time resulting in a greater decrease in mucosal inflammation. This short communication suggests that oral viscous budesonide should be considered as a potential new therapy in the management of oral cGVHD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000000618 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.
Haematologica
September 2025
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Microbiota disruptions have been associated with short-term complications after allogeneic hematopoietic cell transplantation (alloHCT). However, only a few studies have examined the relationship between dysbiosis and chronic graft-versus-host disease (cGVHD), the main long-term immunologic toxicity of alloHCT. Considering the role of oral microbiota in systemic inflammatory diseases, we evaluated whether oral microbiota at day 28 post-HCT corresponding to clinical recovery from the acute events after transplantation is associated with subsequent cGVHD.
View Article and Find Full Text PDFOral Verruciform Xanthoma as a Manifestation of Chronic Graft-Versus-Host Disease in Fanconi Anemia: A Rare Case Report.
Spec Care Dentist
August 2025
Department of Oral Diagnosis and Pathology, School of Dentistry, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Oral verruciform xanthoma (OVX) is an uncommon benign epithelial lesion, typically observed in otherwise healthy individuals. It has occasionally been reported in association with chronic graft-versus-host disease (cGVHD) following hematopoietic stem cell transplantation (HSCT). To date, only 12 cases of OVX associated with cGVHD have been reported in the literature.
View Article and Find Full Text PDFSuccessful use of belumosudil in a patient with chronic ocular GVHD: A case report.
Transpl Immunol
September 2025
Eye Hospital, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China. Electronic address:
Background: Belumosudil is a selective ROCK2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients who have failed at least two prior systemic therapies.
View Article and Find Full Text PDFTwo oral verrucous carcinomas in a patient with oral graft vs. host disease- recurrent verrucous carcinoma: a case report.
BMC Oral Health
July 2025
Department of Periodontics and Oral Medicine, College of Stomatology, Guangxi Medical University, Nanning, Guangxi, China.
Patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) frequently experience immunodeficiency, predisposing them to graft-versus-host disease (GVHD) and viral infection. The oral cavity is a common organ affected by chronic GVHD(cGVHD), which can lead to the development of secondary malignant tumors such as oral squamous cell carcinoma (OSCC). Verrucous carcinoma is a low-grade variant of SCC with specific morphologic, cytokinetic and clinical features.
View Article and Find Full Text PDFInflammatory Markers and Microbiome Dysbiosis in Hematopoietic Cell Transplant Recipients with Lung Graft-versus-Host Disease.
Transplant Cell Ther
September 2025
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Bronchiolitis obliterans (BOS) is a manifestation of pulmonary chronic graft-versus-host disease (cGVHD) and is a devastating complication of allogeneic hematopoietic stem cell transplantation (HCT). Early detection and treatment of BOS may improve outcomes, but biomarkers that accurately identify BOS early are lacking. We aimed to determine whether certain validated cGVHD markers could also accurately diagnose BOS as compared with patients without BOS and with or without extrapulmonary cGVHD.
View Article and Find Full Text PDF